VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1219-1227

  Schmitt, A M ^a   Schmid, S ^a   Rudolph, T ^a   Anlauf, M ^b   Prinz, C ^c   Kloppel G ^b   Moch, H ^a   Heitz, P U ^a   Komminoth, P ^d   Perren, A ^e,f  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF KIEL   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d TRIEMLI HOSPITAL   (Switzerland)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DNA METHYLATION; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PANCREAS ISLET CELL TUMOR; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VON HIPPEL LINDAU DISEASE;

ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; DNA METHYLATION; ENDOCRINE GLAND NEOPLASMS; GENE DELETION; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 72549083643     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0297     Document Type: Article

References (37)

1. Anlauf M, Schlenger R, Perren A, Bauersfeld J, Koch CA, Dralle H, Raffel A, Knoefel WT, Weihe E, Ruszniewski P et al. 2006 Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. American Journal of Surgical Pathology 30 560-574.
2. Arnold CN, Sosnowski A, Schmitt-Graff A, Arnold R & Blum HE 2007 Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-enteropancreatic system. International Journal of Cancer 120 2157-2164. (Pubitemid 46555852)
3. Barghorn A, Komminoth P, Bachmann D, Rutimann K, Saremaslani P, Muletta-Feurer S, Perren A, Roth J, Heitz PU & Speel EJ 2001 Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression. Journal of Pathology 194 451-458. (Pubitemid 32782670)
4. Behrooz A & Ismail-Beigi F 1999 Stimulation of glucose transport by hypoxia: signals and mechanisms. News in Physiological Sciences 14 105-110.
5. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR & Dewhirst MW 1996 Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Research 56 941-943.
6. Brugarolas J & Kaelin WG Jr 2004 Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6 7-10. (Pubitemid 38903157)
7. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR & Rashid A 2003 CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22 924-934. (Pubitemid 36255828)
8. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA et al. 1997 Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 404-407.
9. Chung DC, Smith AP, Louis DN, Graeme-Cook F, Warshaw AL & Arnold A 1997 A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. Journal of Clinical Investigation 100 404-410. (Pubitemid 27349088)
10. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ & Maxwell PH 2000 Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. Journal of Biological Chemistry 275 25733-25741. (Pubitemid 30687077)
11. Corcos O, Couvelard A, Giraud S, Vullierme MP, Dermot OT, Rebours V, Stievenart JL, Penfornis A, Niccoli-Sire P, Baudin E et al. 2008 Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic features. Pancreas 37 85-93.
12. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K et al. 2005 Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. British Journal of Cancer 92 94-101. (Pubitemid 40188441)
13. Couvelard A, Hu J, Steers G, O'Toole D, Sauvanet A, Belghiti J, Bedossa P, Gatter K, Ruszniewski P & Pezzella F 2006 Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. Gastroenterology 131 1597-1610. (Pubitemid 44780863)
14. Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, Babb JS, Grizzle WE & Cairns P 2004 Promoter hypermethylation profile of kidney cancer. Clinical Cancer Research 10 3972-3979. (Pubitemid 38812470)
15. Dutcher JP 2004 Mammalian target of rapamycin inhibition. Clinical Cancer Research 10 6382S-6387S.
16. Francalanci P, Diomedi-Camassei F, Purificato C, Santorelli FM, Giannotti A, Dominici C, Inserra A & Boldrini R 2003 Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. American Journal of Surgical Pathology 27 1386-1389. (Pubitemid 37185831)
17. Glavac D, Ravnik-Glavac M, Ovcak Z & Masera A 1996 Genetic changes in the origin and development of renal cell carcinoma (RCC). Pflügers Archiv 431 R193-R194. (Pubitemid 26140955)
18. Gumbs AA, Moore PS, Falconi M, Bassi C, Beghelli S, Modlin I & Scarpa A 2002 Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. Journal of Surgical Oncology 81 45-53 (discussion 54). (Pubitemid 34983166)
19. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM et al. 1994 Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. PNAS 91 9700-9704. (Pubitemid 24311875)
20. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U & Vaupel P 1996 Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research 56 4509-4515. (Pubitemid 26330463)
21. Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP et al. 2002 Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clinical Cancer Research 8 2595-2604.
22. Johannessen CM, Johnson BW, Williams SM, Chan AW, Reczek EE, Lynch RC, Rioth MJ, McClatchey A, Ryeom S & Cichowski K 2008 TORC1 is essential for NF1-associated malignancies. Current Biology 18 56-62.
23. Lindberg D, Akerstrom G & Westin G 2007 Mutational analyses of WNT7A and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumours. Clinical Endocrinology 66 110-114. (Pubitemid 44952502)
24. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, Pastorek J, Ratcliffe PJ, Stratford IJ & West CM 2001 Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Research 61 6394-6399. (Pubitemid 32783244)
25. Lubensky IA, Pack S, Ault D, Vortmeyer AO, Libutti SK, Choyke PL, Walther MM, Linehan WM & Zhuang Z 1998 Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. American Journal of Pathology 153 223-231. (Pubitemid 28317525)
26. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER & Ratcliffe PJ 1999 The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 271-275.
27. Moore PS, Missiaglia E, Antonello D, Zamo A, Zamboni G, Corleto V, Falconi M & Scarpa A 2001 Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes, Chromosomes and Cancer 32 177-181.
28. Opavsky R, Pastorekova S, Zelnik V, Gibadulinova A, Stanbridge EJ, Zavada J, Kettmann R & Pastorek J 1996 Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 33 480-487. (Pubitemid 26159864)
29. Pastorekova S, Zavadova Z, Kostal M, Babusikova O & Zavada J 1992 A novel quasi-viral agent, MaTu, is a two-component system. Virology 187 620-626.
30. Perren A, Wiesli P, Schmid S, Montani M, Schmitt A, Schmid C, Moch H & Komminoth P 2006 Pancreatic endocrine tumors are a rare manifestation of the neurofibromatosis type 1 phenotype: molecular analysis of a malignant insulinoma in a NF-1 patient. American Journal of Surgical Pathology 30 1047-1051. (Pubitemid 44264957)
31. Perren A, Anlauf M & Komminoth P 2007 Molecular profiles of gastroenteropancreatic endocrine tumors. Virchows Archiv 451 S39-S46. (Pubitemid 47283380)
32. del Peso L, Castellanos MC, Temes E, Martin-Puig S, Cuevas Y, Olmos G & Landazuri MO 2003 The von Hippel-Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. Journal of Biological Chemistry 278 48690-48695. (Pubitemid 41079509)
33. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Eriksson B, Falchetti A, Falconi M, Komminoth P et al. 2006 TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 449 395-401.
34. Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM, Moch H et al. 2007 WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. American Journal of Surgical Pathology 31 1677-1682.
35. Semenza GL 2007 Hypoxia-inducible factor 1 (HIF-1) pathway. Science's STKE 2007 cm8.
36. Speel EJ, Scheidweiler AF, Zhao J, Matter C, Saremaslani P, Roth J, Heitz PU & Komminoth P 2001 Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9Q34 is an early event in insulinomas. Cancer Research 61 5186-5192. (Pubitemid 32681552)
37. Zhang JZ, Behrooz A & Ismail-Beigi F 1999 Regulation of glucose transport by hypoxia. American Journal of Kidney Diseases 34 189-202.